Mounjaro in Johor Bahru

Struggling with weight loss despite diet and exercise? You’re not alone. Obesity is a growing health concern in Malaysia — and now, a breakthrough solution is available right here in Johor Bahru. Mounjaro (tirzepatide) is the first dual-receptor FDA-approved weight loss injection, and LyVin Clinic is among the first in JB to make it accessible.

Why Obesity Needs Urgent Attention in Malaysia
Malaysia has one of the highest obesity rates in Asia, increasing the risks of:

Type 2 diabetes
Heart disease
Fatty liver
Joint problems
Cancer

By addressing obesity early, you’re not just slimming down — you’re protecting your long-term health.

Mounjaro | Mounjaro JB | Mounjaro Treatment JB

Benefits of Small Weight Reduction

Even losing 5–10% of your body weight can:

Improve blood sugar control
Reduce blood pressure
Lower cholesterol
Relieve joint pain
Boost confidence and energy

What Is Mounjaro (Tirzepatide)?

Mounjaro is a once-weekly injectable medication that activates two key hormone receptors (GLP-1 and GIP).
This dual action helps:

Control appetite and cravings
Slow stomach emptying → longer fullness
Improve insulin sensitivity

It is FDA-approved for diabetes and weight management.

Is Mounjaro Available in JB?

Yes. Mounjaro injections are now available at LyVin Clinic, Johor Bahru (Sutera Utama). Patients from both JB and Singapore visit us for safe, doctor-supervised weight management programs.

Mounjaro vs Semaglutide (Wegovy®)

The 7.5% extra weight loss with Mounjaro can mean the difference between improvement and life-changing transformation.

Mounjaro vs Ozempic

Mounjaro® (tirzepatide) is the first and only dual GIP/GLP-1 receptor agonist approved by the U.S. FDA for chronic weight management.

It works in two powerful ways:

GLP-1 Activation → reduces appetite, slows digestion, improves insulin release
GIP Activation → enhances fat metabolism and helps regulate energy storage

This dual-action approach delivers superior results compared to older treatments like semaglutide (Wegovy®).

Clinical Results with Mounjaro

The SURMOUNT clinical trials showed:

–22.5% body weight reduction (average, 72 weeks at 10/15 mg)
Up to 45% visceral fat reduction (dangerous belly fat around organs)
–19.9 cm waist reduction
Over 60% of patients lost >20% of body weight
Improvements in cholesterol, blood sugar, blood pressure, and quality of life

Suitable Candidates for Mounjaro in JB

You may be eligible if you:

Have a BMI ≥30, or
Have a BMI ≥27 with weight-related health conditions (hypertension, high cholesterol, sleep apnea)
Have tried lifestyle changes but need medical support
Do not have contraindications (e.g. severe GI disease, pancreatitis history)